Skip to main content
Triangle logo TriangleGet started

MK-1084 (NCT07252739)

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J): a one-minute explainerNCT072527391 min

MK-1084 trial for Malignant Neoplasm (NCT07252739). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced or metastatic nonsquamous lung cancer carrying KRAS G12C, without prior systemic treatment for advanced disease or prior KRAS-targeted treatment.

The idea: oral MK-1084 blocks mutant KRAS signals; intravenous pembrolizumab releases an immune brake. Patients are randomly assigned to this pair alone, with cetuximab, or with sacituzumab tirumotecan. Researchers assess safety and tumor shrinkage. Archived tissue or a new biopsy is required.

This phase 2 study plans 140 patients. Merck sponsors it; three US sites are recruiting, in Clermont, Fargo, and Sioux Falls.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.